Breaking News

U.S. FDA Approves Life-Threatening Allergic Reaction Treatment

The epinephrine auto-injector is specifically designed for infants and small children

Kaléo Pharma, a privately-held pharmaceutical company, has received FDA approval of its its supplemental New Drug Application for the AUVI-Q 0.1 mg Auto-Injector, the first of its kind in the industry specifically designed for the treatment of life-threatening allergic reactions in infants and small children weighing 16.5 to 33 pounds.   This news comes after the treatment was granted Priority Review by the FDA.  AUVI-Q is a compact auto-injector with features that include a voice...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters